PHARMACY

Prasugrel shows decreased incidence of heart-related death, increased incidence of bleeding

BY Drew Buono

TOKYO and INDIANAPOLIS Results of a new study conducted by Eli Lilly and Daiichi Sankyo for their experimental blood thinner prasugrel showed some positives and negatives when compared to Bristol-Myers Squibb and Sanofi-Aventis’ blood thinner Plavix.

While the drug lowers the risk of cardiovascular death, it does increase the risk of major bleeding in patients when compared to Plavix.

In a study of 13,000 patients taking prasugrel had a 19 percent lower risk of cardiovascular death, nonfatal heart attacks and nonfatal strokes compared to Plavix. But, 2.4 percent of patients taking the drug experienced major bleeding compared to only 1.8 percent for those taking Plavix. Also, life-threatening bleeding occurred in 1.4 percent of patients taking prasugrel compared to 0.9 percent of Plavix patients.

The companies said they had identified three major risk factors for significant bleeding while on prasugrel: patients who were older than 75 years, weighed less than 132 pounds or had a history of transient ischemic attack or stroke. Patients without those risk factors had an equal risk of major bleeding whether they received prasugrel or Plavix.

The companies intend to submit the new drug application for prasugrel to the Food and Drug Administration by the end of the year.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Rite Aid announces program to help seniors with Medicare Part D

BY Michael Johnsen

CAMP HILL, Pa. With the 2008 Medicare Part D Prescription Drug Plan open enrollment period beginning Nov. 15, Rite Aid on Monday announced that their pharmacies will look to playing a key role in educating seniors so they can make informed decisions about the best plan choice for their prescription needs.

“Rite Aid is committed to making sure our senior patients are fully educated and understand the Medicare prescription drug benefit,” stated Mark de Bruin, Rite Aid’s executive vice president of pharmacy. “We’ve teamed up with leaders in the managed care industry to create user friendly, detailed information on the Medicare Part D benefits as well as helpful step by step tips to help them determine the best Medicare Part D plan for their prescription needs. In addition, our 14,000 Rite Aid pharmacists are available to answer questions and offer explanation on the intricacies of the Medicare Part D prescription drug benefit.”

All Rite Aid pharmacies are offering a free detailed Medicare Prescription Drug Plan Guide. In addition, Rite Aid pharmacists are trained on Medicare Part D to help seniors and caregivers navigate through the numerous plan options. Rite Aid also has a special website, www.riteaid.com/medicareadvisor, which allows patients to compare drug prices and get a complete list of plan options offered in their local area. Some Plans include a link to online enrollment forms.

To help educate its pharmacy patients 65 years and older on the various Medicare Part D Prescription Drug Plan options, Rite Aid has partnered with AARP/United Healthcare, Aetna and Wellpoint to provide detailed and useful in-store educational materials.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

FDA committee to examine new indication for Avastin

BY Allison Cerra

WASHINGTON The FDA’s Oncologic Drugs Advisory Committee is set to review Genentech’s cancer drug, according to reports.

The advisory committee, which will meet Dec. 5, is said to discuss a new indication for Genentech’s cancer drug Avastin.

The company recently submitted an additional biologics license application for Avastin (bevacizumab) to treat patients who have not received chemotherapy for certain types of breast cancer.

Genentech has experienced some backlash from wholesalers and pharmacies over the drug, which is chemically similar to the company’s drug Lucentis, used to treat macular degeneration, a severe eye condition that usually occurs at a later age.

Although Avastin is not approved for ophthalmologic use, physicians use it instead of Genentech’s chemically similar drug Lucentis (ranibizumab), which is considerably more expensive.

Chairman for the Senate Special Committee on Aging, Herb Kohl, D-Wis., opposed the company’s new policy, saying it would cost taxpayers billions of dollars through higher Medicare costs.

Genentech said it would delay implementing its new distribution policy until Jan. 1, 2008.

In the first six months of this year, Avastin had sales of $1.1 billion and Lucentis had sales of $420 million.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?